AVANT Therapeutics

Avant Therapeutics is a biotechnology company focused on developing next-generation AAV-based gene therapies for rare and prevalent diseases. The company utilizes its proprietary AAV-S platform to engineer synthetic capsids with improved tissue specificity, reduced immunogenicity, and enhanced transduction efficiency. Its lead programs target ophthalmic conditions like wet age-related macular degeneration and neuromuscular disorders such as Pompe disease and spinal muscular atrophy. Avant Therapeutics aims to overcome the limitations of current viral vectors to provide more effective and safer genetic medicines. The company maintains operations in both Seoul, South Korea, and San Diego, California, to leverage global expertise in gene therapy development.